Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors.

ABSTRACT:

Background

Convalescent plasma is undergoing randomized trials as a potential therapeutic option for COVID-19 infection. Little empirical evidence exists regarding the determination of donor eligibility and experiences with donor selection.

Study design and methods

This prospective study was conducted at a tertiary care hospital in New York to select plasma donors for a randomized, double-blind, controlled convalescent plasma trial. Clearance for donation required successful completion of an online questionnaire and an in-person screening visit, which included (a) completion of a Donor Health Questionnaire (DHQ), (b) Immunoglobulin G (IgG) antibody testing using an immunochromatographic anti- severe acute respiratory coronavirus 2 (SARS-CoV-2) test, (c) Polymerase chain reac

SUBMITTER: Carter JA 

PROVIDER: S-EPMC8013201 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature